These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 25971769)
1. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors. Therrien E; Larouche G; Nguyen N; Rahil J; Lemieux AM; Li Z; Fournel M; Yan TP; Landry AJ; Lefebvre S; Wang JJ; MacBeth K; Heise C; Nguyen A; Besterman JM; Déziel R; Wahhab A Bioorg Med Chem Lett; 2015 Jun; 25(12):2514-8. PubMed ID: 25971769 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton. Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2. Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106 [TBL] [Abstract][Full Text] [Related]
4. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT. Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574 [TBL] [Abstract][Full Text] [Related]
5. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2. Huhtiniemi T; Salo HS; Suuronen T; Poso A; Salminen A; Leppänen J; Jarho E; Lahtela-Kakkonen M J Med Chem; 2011 Oct; 54(19):6456-68. PubMed ID: 21895016 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in inhibitors of sirtuin1/2: an update and perspective. Zhou Z; Ma T; Zhu Q; Xu Y; Zha X Future Med Chem; 2018 Apr; 10(8):907-934. PubMed ID: 29642711 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities. Yoon YK; Ali MA; Wei AC; Choon TS; Osman H; Parang K; Shirazi AN Bioorg Med Chem; 2014 Jan; 22(2):703-10. PubMed ID: 24387981 [TBL] [Abstract][Full Text] [Related]
8. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2. Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719 [TBL] [Abstract][Full Text] [Related]
9. Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor. Park JB PLoS One; 2016; 11(3):e0150392. PubMed ID: 26986569 [TBL] [Abstract][Full Text] [Related]
10. Tetrahydroindoles as Multipurpose Screening Compounds and Novel Sirtuin Inhibitors. Vojacek S; Schulig L; Wössner N; Geist N; Langel W; Jung M; Schade D; Link A ChemMedChem; 2019 Apr; 14(8):853-864. PubMed ID: 30811852 [TBL] [Abstract][Full Text] [Related]
11. Non-specific SIRT inhibition as a mechanism for the cytotoxicity of ginkgolic acids and urushiols. Ryckewaert L; Sacconnay L; Carrupt PA; Nurisso A; Simões-Pires C Toxicol Lett; 2014 Sep; 229(2):374-80. PubMed ID: 24998427 [TBL] [Abstract][Full Text] [Related]
12. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356 [TBL] [Abstract][Full Text] [Related]
13. Virtual screening approach of sirtuin inhibitors results in two new scaffolds. Kokkonen P; Kokkola T; Suuronen T; Poso A; Jarho E; Lahtela-Kakkonen M Eur J Pharm Sci; 2015 Aug; 76():27-32. PubMed ID: 25936698 [TBL] [Abstract][Full Text] [Related]
14. Molecular docking and dynamics simulation, receptor-based hypothesis: application to identify novel sirtuin 2 inhibitors. Sakkiah S; Thangapandian S; Park C; Son M; Lee KW Chem Biol Drug Des; 2012 Aug; 80(2):315-27. PubMed ID: 22564257 [TBL] [Abstract][Full Text] [Related]
15. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD Mellini P; Itoh Y; Elboray EE; Tsumoto H; Li Y; Suzuki M; Takahashi Y; Tojo T; Kurohara T; Miyake Y; Miura Y; Kitao Y; Kotoku M; Iida T; Suzuki T J Med Chem; 2019 Jun; 62(12):5844-5862. PubMed ID: 31144814 [TBL] [Abstract][Full Text] [Related]
16. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins. Botta G; De Santis LP; Saladino R Curr Med Chem; 2012; 19(34):5871-84. PubMed ID: 22998567 [TBL] [Abstract][Full Text] [Related]
17. 1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors. Zheng YC; Wang LZ; Zhao LJ; Zhao LJ; Zhan QN; Ma JL; Zhang B; Wang MM; Wang ZR; Li JF; Liu Y; Chen ZS; Shen DD; Liu XQ; Ren M; Lv WL; Zhao W; Duan YC; Liu HM Cell Physiol Biochem; 2016; 38(1):185-93. PubMed ID: 26784898 [TBL] [Abstract][Full Text] [Related]
18. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2. Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764 [TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of small molecule SIRT3-specific inhibitors as revealed by mass spectrometry. Loharch S; Chhabra S; Kumar A; Swarup S; Parkesh R Bioorg Chem; 2021 May; 110():104768. PubMed ID: 33676042 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Choi G; Lee J; Ji JY; Woo J; Kang NS; Cho SY; Kim HR; Ha JD; Han SY Int J Oncol; 2013 Oct; 43(4):1205-11. PubMed ID: 23900402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]